VERIMATRIX
5.6.2019 07:02:05 CEST | Business Wire | Press release
Verimatrix, the leader in redefining the standard for connected devices and services with an innovative combination of security and data analytics, and IPTV technology company Ocilion today announced two large Austrian operators as their latest customers. kabelplus and Salzburg AG have each selected on-premise IPTV solutions from Ocilion that are secured by Verimatrix, enabling more flexible and future-proof video delivery models.
Both operators opted independently for on-premise deployments hosted in their distinctive infrastructures, optimally suiting larger volumes of subscribers using Ocilion’s new homogenous P400 family of 4K set-top boxes (STBs), which combines innovation, design, functionality and efficiency. The advanced and adaptable technology offers the flexibility needed to support various delivery models, whether hybrid, FTTH or OTT, while the integrated Verimatrix client supports digital rights management (DRM) for IP, IP/DVB-C and OTT.
“kabelplus and Salzburg AG came to us with unique challenges and needs that will grow and evolve as consumer demands and security requirements continue to rapidly shift,” said Hans Kühberger, CEO of Ocilion. “We are very pleased to fulfil their demands for increasingly sophisticated modern and high-end IPTV services with our future-proof on-premise solution, including our new P400 family and resolve complex security requirements in partnership with Verimatrix.”
The decision for kabelplus, the largest cable network provider in Lower Austria and Burgenland, to launch its own IPTV product resulted from the need to extend its portfolio for its HFC network with extra products and services, and it came during the middle of a FTTH expansion and rollout. In need of a competitive edge to reinforce its position as a top service provider, kabelplus saw the Ocilion-Verimatrix partnership as the perfect fit to elevate its product portfolio with new premium features and bundling options.
When live-only DVB-C delivery was no longer enough to support Salzburg AG’s consumer demands, the Salzburg energy, transport and telecommunications provider turned to Ocilion and Verimatrix to set the foundation for it to be able to offer premium service enhancements and maximize upselling opportunities with long-term adaptability.
With these deployments, the Austrian operators are also laying the foundation for secure UHD ecosystems with OcilionsP400 line of STBs having officially received the Verimatrix 4.0 Ultra Security certification. This certification emphasizes their readiness to fully meet UHD security requirements, ensuring that they meet UHD content guidelines set by MovieLabs’ Specifications for Next Generation Video and Enhanced Content Protection.
“Achieving Ultra Security certification means that Ocilion’s advanced STBs are trusted to deliver premium content to kabelplus and Salzburg AG consumers at the highest quality possible and in accordance with the strongest security requirements specified by premium rights holders,” commented Verimatrix COO Steve Oetegenn. “Ultimately, the combined strengths of Ocilion and Verimatrix presents a formidable barrier against piracy in a form that can be updated readily to ensure these operators are able to keep pace with the evolving threat landscape.”
About Ocilion
Ocilion is a software company, providing individual end-to-end IPTV platforms to network providers in German-speaking Europe (Germany, Austria, Switzerland & Liechtenstein) since 2004. The white labelled IPTV platform is suited for all network topologies (HFC, FTTH, VDSL, OTT) and contains content, services, premium TV features (Replay, PVR, VoD), a full family of pre-integrated 4K set-top boxes and apps (smartphone, tablet, Apple TV, Amazon Fire TV). Operators can choose between on-premise systems (hosted in their distinctive infrastructure) and a rental option hosted by Ocilion (optimised for medium-sized carriers). Since 2009, the IPTV specialist started IPTV building solutions for hotels, hospitals, ships, corporate buildings and other projects (iptv500 product). For more information, visit www.ocilion.com .
About Inside Secure/Verimatrix
Inside Secure/Verimatrix (Euronext Paris – INSD) is redefining the standard for connected devices and services with an innovative combination of security and data analytics that maximizes revenues, protects reputations and enables growth. The company serves a range of industries and markets, including entertainment, mobile, computer networks and internet of things (IoT). The company offers easy-to-use software solutions, cloud services and silicon IP that provides unparalleled security and business intelligence. With more than 24 years of experience and a solid reputation, Inside Secure/Verimatrix protects customers’ most valuable content, transactions, applications, and communications. With 18 office locations in 12 countries supporting more than 1,200 customers, the company is uniquely positioned to secure and enable the connected future. For more information, visit www.insidesecure.com and www.verimatrix.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604006167/en/
Contact:
Kelly Foster, Verimatrix +1 619 224 1261 kfoster@verimatrix.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom